Texas MPN Workshop 2022 | Ongoing trials and novel agents being explored in advanced and indolent systemic mastocytosis
In this video, Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, highlights ongoing clinical trials and novel agents being explored for the treatment of systemic mastocytosis (SM). Dr Radia first discusses the ongoing APEX trial (NCT04996875) which is evaluating bezuclastinib in patients with advanced SM, and then goes on to discuss treatment approaches for indolent SM. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Advisory Board and Honoraria: Novartis, Consultant and Honoraria: Blueprint Medicines, Cogent Biosciences.
Study response adjudication committees : EXPLORER/PATHFINDER – Blueprint Medicines and APEX -Cogent Biosciences.
